Circulating tumor cells and clinical outcomes in men with metastatic hormone sensitive prostate cancer treated with enzalutamide and docetaxel: Analysis of the ENZADA trial.

Authors: Landon Carter Brown, Claud Grigg, Danielle Boselli, James Thomas Symanowski, Jason Zhu, Sarah Norek, Xhevahire J. Begic, Derek Raghavan, Earle F. Burgess

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e17093

Source: Full article

---

Abstract

e17093